What is Breakthrough Therapy Designation (BTD)?
An FDA expedited program for drugs treating serious conditions with substantial early efficacy.
BTD grants intensive FDA guidance and rolling review to drugs showing substantial improvement over existing therapy on a clinically significant endpoint in early evidence. It is granted per indication, not per drug.
BTD announcements are positive catalysts but do not change approval standards — the most common retail misread in the sector.
See it live: the catalyst calendar · status-change feed